Multiple Sclerosis (cont.)
Fernando Dangond, MD
Melissa Conrad Stöppler, MD
Melissa Conrad Stöppler, MD
Melissa Conrad Stöppler, MD, is a U.S. board-certified Anatomic Pathologist with subspecialty training in the fields of Experimental and Molecular Pathology. Dr. Stöppler's educational background includes a BA with Highest Distinction from the University of Virginia and an MD from the University of North Carolina. She completed residency training in Anatomic Pathology at Georgetown University followed by subspecialty fellowship training in molecular diagnostics and experimental pathology.
In this Article
What are the treatments for multiple sclerosis?
Comment on this Read 23 Comments
There are many issues for the patient and physician to consider in treating multiple sclerosis. Goals may include:
Most neurologists will consider treatment with DMDs once the diagnosis of relapsing-remitting multiple sclerosis is established. Many will begin treatment at the time of the first attack of MS since clinical trials have suggested that patients in whom treatment is delayed may not benefit as much as patients who are treated early.
It is important for patients to talk to their doctor before deciding to go on therapy since DMDs differ in their uses (for example, one DMD may be used for slowing progressing disability but not for treatment of the first attack of MS; another DMD may be used for reducing relapses but not for slowing progressing disability). Finally, utilizing support groups or counseling may be helpful for patients and their families whose lives may be affected directly by multiple sclerosis.
Once goals have been set and a decision regarding DMDs has been made, initial therapy may include medications to manage attacks, symptoms, or both. An understanding of the potential side effects of drugs is critical for the patient because sometimes side effects alone deter patients from drug therapy. Patients may choose to avoid drugs altogether or choose an alternative drug that may offer relief with fewer side effects. A continuous dialogue between the patient and physician about the medications is important in determining the needs for treatment.
Although the efficacy of DMDs has been proven in clinical trials, their ability to decrease the frequency of relapses varies in patients with relapsing MS. It is difficult to clearly delineate these differences in the absence of comparative clinical trials, and physicians should consider this limitation in interpreting the reported relapse reduction rates from individual placebo-controlled trials. It is not acceptable to compare data across trials; however, the following relapse reduction rates vs. placebo for some of the DMDs from the pivotal trials are provided for general information purposes:
In head-to-head trials in patients with relapsing MS, both Rebif and Gilenya have shown superiority to Avonex in reducing relapse rates and MRI lesions (EVIDENCE and TRANSFORMS trials, respectively).
Drugs known to affect the immune system have become the primary focus for managing multiple sclerosis. Initially, corticosteroids, such as prednisone (Deltasone, Liquid Pred, Deltasone, Orasone, Prednicen-M) or methylprednisolone (Medrol, Depo-Medrol), were widely used. However, since their effect on the immune system is nonspecific (general) and their use may cause numerous side effects, corticosteroids now tend to be used to manage only severe multiple sclerosis attacks (that is, attacks leading to physical disability or causing pain).
Medically Reviewed by a Doctor on 8/1/2014
Viewers share their comments
Multiple Sclerosis - Symptoms Question: The symptoms of multiple sclerosis can vary greatly from patient to patient. What were your symptoms at the onset of your disease?
Multiple Sclerosis - Treatments Question: How do you manage your multiple sclerosis?
Multiple Sclerosis - Diagnosis Question: How many doctors did you go to before you received a multiple sclerosis diagnosis?
Multiple Sclerosis - Causes Question: Were you, a friend, or relative diagnosed with MS? What do you think the cause might be?